Skip to main content

Frohlich Tom's Form 4 filing

Chinook Therapeutics, Inc. (KDNY) · filed Feb 2, 2023

Accession no.
0001209191-23-006375
Filed
Feb 2, 2023
Trade date
Jan 31, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions and 3 derivative transactions. Open-market sales total $112.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Frohlich TomCIK 0001823925Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 31, 2023Common StockMOption exerciseAcquired+8,333–F1–152,240Direct
Jan 31, 2023Common StockSSaleDisposed−4,566$24.68−$112,688.88147,674Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 31, 2023Common StockMOption exerciseDisposed−8,333$0.00$016,667Direct
Jan 31, 2023Common StockAGrant or awardAcquired+84,000$0.00$084,000Direct
Jan 31, 2023Common StockAGrant or awardAcquired+21,000$0.00$021,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)